Heterogeneity of ILC2s in the Lungs

Masato Asaoka, Hiroki Kabata* and Koichi Fukunaga

Division of Pulmonary Medicine, Department of Medicine, Keio University School of Medicine, Tokyo, Japan

Group 2 innate lymphoid cells (ILC2s) express transcription factor GATA3 and produce type 2 cytokines upon stimulation with epithelial cell-derived cytokines, including IL-33 and IL-25. ILC2s, which were first characterized by three different research groups in 2010 (1–3), are distributed throughout the body, such as in the lungs, skin, intestine, liver, brain, bone marrow, and peripheral blood in mice and humans (1–13). In particular, ILC2s play a critical role in innate immunity-mediated type 2 airway inflammation (1–8, 10–12) and contribute to the repair of airway damage via amphiregulin production after influenza virus infection (14). Recent studies have shown that ILC2s are associated with lung fibrosis, chronic lung obstructive disease exacerbation, and lung cancer (15–23). Thus, ILC2s have various functions and are involved in the pathogenesis of several lung diseases.

ILC2s are primarily tissue-resident cells with different characteristics depending on the tissues in which they exist (24–27). In mice, ILC2s express higher levels of Il1rl1, which encodes the IL-33 receptor subunit ST2, in the lungs than in other tissues (27, 28). Conversely, the expression levels of Il17rb, which encodes an IL-25 receptor subunit, and Il18r1, which encodes an IL-18 receptor subunit, are lower in ILC2s in the lungs than in the small intestine and skin, respectively (27). Indeed, intranasal administration of IL-33 potently activates ILC2s in the lungs compared with IL-25 or IL-18 (27, 29, 30). Interestingly, when IL-25 is administered intraperitoneally (but not...
intrasinally), an intestine-derived unique ILC2 subset (called inflammatory ILC2s [iILC2s]), which highly expresses KLRG1 and IL-17RB, migrates to the lungs (31). Moreover, recent single-cell RNA-seq analyses in mice and humans have revealed the existence of diverse cell populations among lung ILC2s (27, 32–38). Although ILC2s were previously considered to be a single-cell population, these results confirm the presence of different subsets within ILC2s. Therefore, it is necessary to dissect individual cell populations to evaluate their molecular mechanisms and relationships with diseases.

In this review, we provide a current overview of the heterogeneity of ILC2s in the lungs, and summarize our understanding of the diversity of ILC2s and their contribution to immunity in the lungs.

Differences in ILC2s Across Tissues and Heterogeneity of Lung ILC2s at Steady State

ILC2s are distributed in various organs of the body at a steady state. A recent study comparing the expression of various genes in murine ILC2s in various tissues, such as lung, skin, adipose, skin, intestine, and bone marrow, showed that the expression levels of Gata3 and Il17r do not differ among ILC2s in each tissue; however, hundreds of genes are differentially expressed by ILC2s depending on the localized tissue (27). In particular, lung ILC2s display increased expression of Il1rl1, while intestinal ILC2s highly express Il17rb as well as Ahr and Nmur1, which encode aryl hydrocarbon receptor (AHR) and neuromedin U receptor 1 (NMUR1), respectively (27, 38, 39). Indeed, intranasal administration of IL-33 potently activates lung ILC2s compared with IL-25, while genetic ablation of Ahr or Nmur1 modifies anti-helminth immunity via intestinal ILC2s (38, 39). In addition, most skin ILC2s that express lower levels of Il1rl1 and Il17rb also show increased expression of Il18r1, which encodes an IL-18 receptor subunit (27). Interestingly, the tissue-specific features of ILC2s are independent of either the microbiome or epithelial cell-derived cytokines, including IL-25, IL-33, and thymic stromal lymphopoietin (TSLP). However, neuropilin-1 (Nrp1) was recently identified as a candidate gene that determines the tissue specificity of lung ILC2s and enhances the expression of IL-33 receptor (40). NRP1 can be induced postnatally and its expression is maintained in the lung environment by TGF-β signaling, resulting in the establishment of tissue specificity by lung ILC2s (40). These findings suggest that the diversity of ILC2s depends on the tissue in which they reside, and that acquisition of tissue specificity may begin very early in development (Figure 1).

During the development of ILC2s in the lungs, ILC progenitors migrate to the lung before birth and differentiate into ILC2s depending on IL-7 signaling (41). These prenatal ILC2s persist after birth, and are detectable in adult mice, however, they account for a small proportion and decrease further with age. After birth, acute expansion and activation of ILC2s occur in the lungs between 2 and 3 weeks of age, and these neonatal ILC2s have high expression of genes related to cytokine production, immunoregulation, and proliferation, such as Ifnγ, Il13, Nr4a1, and Mki67, as well as Cxcl2, a neutrophil recruitment factor, which induces other immune cells into the lung and contributes to the development of the lung environment (41, 42). According to the fate-mapping approach, neonatal ILC2s are long-lived and tissue-resident and constitute the majority of lung ILC2s, even in adults (41). In adult mice, the proportion of neonatal ILC2s is gradually diluted by newly generated ILC2s, termed adult-derived ILC2s, and the adult lungs contain a diverse mixture of prenatal, neonatal, and adult-origin ILC2s. However, the turnover speed of ILC2s varies depending on the tissue and is slower in the lungs than in the skin, small intestine, and bone marrow. Therefore, the proportion of neonatal ILC2s is high in the lungs, and neonatal ILC2s play a major role in enhancing type 2 inflammation through local expansion in the lungs (41).

To assess the diversity of lung ILC2s at a steady state, a study performed single-cell RNA-seq analysis of lung ILC2s from adult mice, which revealed that lung ILC2s can be divided into several subgroups, including a group that highly expresses Cxcl2, Il2, Klf2, and Cd69; a group that expresses Areg, Calca, and Csf2; and a group that expresses Ifnγ, Il13, Caca, Areg, and Cxcl2 (32). However, it is not clear whether these are groups of cells at different developmental stages or activation states. This study also identified a small number of ILC progenitors with low expression of Gata3 and Il1rl1, and high expression of Il18r1 in the lungs (32). These cells express ILC progenitor marker genes, such as Tcf7 and Zbtb16, as well as genes that suggest a mixed lineage potential, such as Rorc and Tbx21. Although these
cells account for less than 2% of ILCs (Lin-IL7R+ cells), trajectory analysis suggests that these cells lose progenitor markers, such as Cd7, Il18r1, Tc7, and Zbtb16, gradually increase the expression of Gata3, Il1rl1, Klrq1, and Bcl11b, and differentiate into mature ILC2s (Figure 1). Therefore, these data suggested that local ILC progenitors differentiated and matured towards ILC2s within the lung tissue (32).

While ILC2s are the dominant population of ILCs in murine lungs, percentage of ILC2s among lung-resident innate lymphocytes in human is around 30% (13, 35, 36, 43). Human ILC2s express Il1rl1, Il17rb, Klrq1, Gata3, and Ptgd2r, which encode CRTH2, however, there is diversity in the expression of various genes depending on the localized tissues (33–36, 44). Specifically, human lung ILC2s show higher expression levels of Il1rl1, Il17rb, and Il13 than tonsil and blood ILC2s (34–36). In addition, Slamf1, Tnfrsf9, Ffar3, and Pparg expression are upregulated in human lung ILC2s. Slamf1 (CD150), encoded by Slamf1, belongs to the signaling lymphocytic activation molecule (SLAM) family that modulates the activation of immune cells, including T cells (34, 45). Tnfrsf9 encodes the activation-induced surface receptor Tnfrsf9, which was originally found in activated T cells (34, 46). Ffar3 and Pparg are lipid metabolism-related genes that regulate the immune cells (47–49). Therefore, the upregulation of these four genes implies a tendency for cell activation. In contrast, human blood ILC2s show high expression levels of Ptgd2r, Sipr2, and Ccr2, which are migration markers (33, 34). While CRTH2 is one of the representative surface markers of human ILC2s, the expression of CRTH2 in blood ILC2s is downregulated after stimulation with a combination of IL-2, IL-25, IL-33, and TSLP, suggesting that CRTH2 expression is negatively correlated with ILC2 activation (34). Among lung ILC2s, approximately 35% of ILC2s lack CRTH2 expression (34). Based on these findings, human lung ILC2s may be relatively activated even in the steady state.

Although the diversity within human lung ILC2s has not been well studied due to their small number, a human study of single-cell RNA-sequence analysis using fetal samples following elective medical termination of pregnancy has been recently reported (33). In this study, fetal lung ILC2s were divided into five subgroups: Pre-ILC2s, Crtth2-ILC2s, Ptgs2-ILC2s, Ccr9-ILC2s, and Kit-ILC2s. Pre-ILC2s highly express Prss57 and Sipk2, which are associated with stem cell signaling and are suggested to be ILC2 progenitors. Pre-ILC2s were further divided into two subgroups according to the expression levels of Mk167, Ptgd2r, and Bcl11b, indicating that immature Pre-ILC2s differentiate into restricted ILC2 progenitors, thereby upregulating the expression of these three genes. Crtth2-ILC2s and Ptgs2-ILC2s had high expression levels of Ptgd2r, and can be considered as conventional ILC2s. In particular, Crtth2-ILC2s exhibited the highest expression levels of Il1rl1 and Il13, and Ptgs2-ILC2s expressed high levels of Ptgs2, which encodes Cox2. Ccr9-ILC2s and Kit-ILC2s are unconventional ILC2s because of low expression levels of Ptgd2r. Ccr9-ILC2s are a rare population of lung ILC2s that express T cell marker genes, including Cd1e, Cd2, Cd3g, Cd4, and Cd8a; however, their biological roles are unknown. Kit-IILC2s express Ccr6 and Ltb and show plasticity, converting into IL-17"ILC3-like cells, suggesting that Kit-IILC2s may be involved in ILC2 plasticity. Thus, it has been reported that there is diversity in the lung ILC2s of human fetuses; however, the relationship to disease and diversity in adults has not yet been determined.

**HETEROGENEITY OF ACTIVATED ILC2s IN THE LUNGS**

Various stimuli, such as allergens and viruses, induce the release of epithelial cell-derived cytokines, including IL-25 and IL-33. These cytokines enhance the phosphorylation of Gata3 via the NF-κB and MAPK signaling pathways in ILC2s (50), which induces cell proliferation and production of type 2 cytokines, such as IL-5 and IL-13. Although murine lung ILC2s express Cd25, Cd90.2, Cd127, Klrq1, Sca-1, and St2, the expression levels of these surface markers vary depending on the mouse strain and sex. Furthermore, they vary largely with the type of stimulation; intranasal administration of IL-33, house dust mite, or Alternaria alternata extract induced the different expression levels of surface markers, including Cd25 and Klrq1, depending on the stimuli (51). In addition, a recent study evaluated the diversity of activated lung ILC2s in mice treated with IL-33 or IL-25 using single-cell RNA-seq analysis and flow cytometry (38). Intranasal administration of IL-25 or IL-33 increased the expression of Il5, Il13, Klrq1, Arg1, and Areg genes, as well as Gp49 and Batf, and some subsets of ILC2s also increased Mhc class 2 and Ctla4. Interestingly, Nmur1 was highly expressed in lung ILC2s at the steady state and after IL-25 stimulation; however, it was downregulated by IL-33. Furthermore, the expression of semaphorin 4a was reduced by IL-33 stimulation. These results suggest that activated ILC2s can alter the expression of various genes and surface markers, depending on the stimulus.

**Nippostrongylus brasiliensis** (*N. brasiliensis*) causes migratory helminth infection in mice. Within hours of entry through the skin, *N. brasiliensis* stage 3 larvae migrate via the blood stream to the lung and alveolar space, causing local tissue damage and hemorrhage on days 1–2 post infection. Maturing larvae are then transported up the airways and swallowed to take up residence in the small intestine on days 4–7 post infection to allow adult reproduction before eventual expulsion. It has been reported that *N. brasiliensis* infection or an intraperitoneal injection of IL-25 induces a different subtype of ILC2s in the lungs and mesenteric lymph nodes, termed inflammatory ILC2s (iiLC2s) (31). iiLC2s are undetectable in the lungs at the steady state and have high expression of Klrq1 and IL-17rb; however, they have low expression of St2 and Sca-1. Notably, iiLC2s are circulating cells that arise from gut ILC2s residing in the intestinal lamina propria, and migrate to diverse tissues based on sphingosine 1-phosphate (S1P)-mediated chemotaxis (52). iiLC2s contribute to the regulation of anti-helminth immunity by producing type-2 cytokines similar to lung ILC2s, that are called natural ILC2s.
(nILC2s), to distinguish them from iILC2s. Furthermore, iILC2s express not only GATA3, but also intermediate levels of RORγt, suggesting that iILC2s carry out both nILC2-like and ILC3-like functions. Indeed, iILC2s produce IL-17 after an oral Candida albicans infection and contribute to antifungal immunity (31).

Recently, IL-33 was reported to promote the generation of iILC2s via induction of tryptophan hydroxylase 1 (Tph1). Ablation of Tph1 resulted in the impairment of iILC2 responses via modified expression of ICOS and increased susceptibility to N. brasiliensis infection (53).

Two studies investigated the heterogeneity of lung ILC2s during an N. brasiliensis infection using single-cell RNA-seq analysis (32, 54). In the first study, lung ILC2s were divided into four groups based on their gene clusters: resting nILC2s, IIL5\textsuperscript{high} nILC2s, IIL13\textsuperscript{high} nILC2s, and iILC2s (54). IIL5\textsuperscript{high} nILC2 populations increased early after the N. brasiliensis infection (day 2), however, this proportion gradually decreased. On day 5, iILC2 populations transiently increased and became the major component of lung ILC2s. iILC2s, however, were undetectable on day 9, and IIL13\textsuperscript{high} nILC2 populations increased thereafter (days 9 and 14) (Figure 2). Similarly, another study showed that the populations of iILC2s expressing Calca, Csf2, and Cxcl2 increased on day 4 of the N. brasiliensis infection, whereas the populations of blood-derived circulating iILC2s expressing Klrk1 increased on days 7 and 10 (32).

On day 15, various subtypes of ILC2s were induced. Interestingly, fate mapping revealed that ILC2s on days 4 and 15 were differentiated from ILC progenitors in the lung rather than being replenished from the bone marrow. Thus, the diversity of ILC2s changes dynamically over time during N. brasiliensis infections.

Although there are no studies on the diversity of activated lung ILC2s in humans, a recent study reported that most resting ILC2s in humans express CD45RA; however, there is a large population of ILC2s expressing CD45RO in inflammatory mucosal tissues, including nasal polyps (55). The transcriptomic features of these cells were similar to those of mouse iILC2s, and peripheral blood-derived resting ILC2s expressed CD45RO in response to the stimulation. Thus, CD45RO may be a useful activation marker for human ILC2s.

As described previously, ILC2s produce type 2 cytokines in a GATA3-dependent manner upon stimulation with IL-33 or IL-25; however, their properties are known to be greatly altered by the surrounding cytokine environment. ILCs are divided into three groups according to their transcription factors and functions: ILC1s, ILC2s, and ILC3s; however, ILCs have plasticity, and can acquire the properties of other ILCs.

First, upon exposure to viruses, bacteria, or noxious agents, such as cigarette smoke, murine lung ILC2s convert to an ILC1-like phenotype with decreased expression of GATA3 and IL-33 receptor ST2, increased expression of T-bet, and the ability to produce IFN-γ (18). This conversion to an ILC1-like phenotype is mediated by stimulation with IL-1β, IL-12, or IL-18 (18, 56). Human ILC2s also acquire an ILC1-like phenotype via IL-1β, IL-12, and IL-18 (57, 58). Indeed, ILC1 populations are reported to increase in patients with chronic obstructive pulmonary disease (COPD), suggesting that ILC2s may be converted to ILC1s owing to the influence of cigarette smoke (18).

Second, a combination of IL-33 with leukotriene C4 or D4 can induce IL-17-producing ILC2s termed ILC2\textsubscript{17} in mice. Unlike Th17 cells or ILC3s, ILC2\textsubscript{17} are independent of RORγt expression (59). ILC2\textsubscript{17} produce IL-17, IL-5, and IL-13 by an intranasal administration of IL-33 or papain; however, Ahr-deficient ILC2s produce limited amounts of IL-17 since Ahr is essential for the induction of ILC2\textsubscript{17}. In humans, IL-2, IL-1β, IL-23, and TGF-β stimulation induces peripheral blood-derived ILC2s to convert to C-Kit+ NKp44+ ILC3-like cells that have the ability to produce IL-17 (60).

Recently, IL-10-producing ILC2s termed ILC2\textsubscript{10} were found in the lungs of mice after an intranasal administration of IL-33 or papain (61). In IL-33-treated mice, ILC2\textsubscript{10} represent a major proportion of IL-10-producing cells, and ILC2\textsubscript{10} can suppress activated ILC2s directly via IL-10. However, ILC2\textsubscript{10} also have the ability to produce type 2 cytokines upon stimulation by IL-33 and TSLP. Mechanistically, retinoic acid (RA) and IL-2 induce ILC2\textsubscript{10}, whereas TGF-β inhibits IL-10 production (62). RA also induces IL-10-producing ILC2s in human ILC2s, suggesting that RA plays an important role in ILC2\textsubscript{10} generation (61).

Together, ILC2s change their phenotype dramatically depending on the surrounding environment. These phenotypical changes may constitute a part of heterogeneity of ILC2s both in the steady state and activated state. However, while effector function of each phenotypical plasticity in vitro was reported, distinct role in vivo remained unclear. Therefore, further survey is awaited.
HETEROGENEITY OF LUNG ILC2s POST INFLAMMATION

ILC2s are diverse even after they are activated once. Recent studies have shown that lung ILC2s can acquire immunological memory. In mice, some activated lung ILC2s mediated by an intranasal administration of papain or IL-33 have the ability to induce strong ILC2-mediated inflammation against secondary challenge. These cells exhibit immunological memory properties and are termed “memory-like ILC2s” (63). Memory-like ILC2s do not exhibit antigen specificity and respond strongly to a second stimulus regardless of the allergen type.

Memory-like ILC2s have some genetical similarities with activated ILC2s but they are resting cells unlike activated ILC2s. Memory-like ILC2s have higher expression levels of Il1r2, Il5, Tnfsf18, Bcl2alb, Bcl2al1d, Ler3, Synel, and Il17rb compared to those of naïve ILC2s, suggesting that memory-like ILC2s are activated. Since the expression of Il17rb is enhanced in memory-like ILC2s, they produce type 2 cytokines upon IL-25 stimulation, whereas naïve ILC2s do not respond to IL-25 stimulation alone (63).

Although S1pr1, Il6st, Cd2, Cd7, and Sell expression are lower in both activated ILC2s and memory-like ILC2s than naïve ILC2s, the expression of cell cycle-related genes including Mki67 and Ccnb2, and the chemokine genes including Ccl17, Ccl24, Cxcl3, and Ccl6 are lower in memory-like ILC2s compared to that in activated ILC2s, suggesting that memory-like ILC2s do not proliferate or produce chemokines as much as activated ILC2.

On the contrary, repetitive stimulation induces hyporesponsive phenotypes of ILC2s, which are termed “exhausted-like ILC2s” (64). This subset of ILC2s expresses high levels of Il10 and Tigit, which are considered exhaustion markers. In addition, they express higher levels of PD-1, GITR, and KLRG1 than those in naïve ILC2s. In contrast to ILC245s, exhausted-like ILC2s are incapable of producing type 2 cytokines. A previous report showed that exhausted-like ILC2s could be collected from mice intranasally instilled with 100 µg papain every three days (64). On day 7 after the administration of the three papain doses, exhausted-like ILC2s emerged in bronchoalveolar lavage (BAL) fluid only. In addition, papain administration every three days for a month induced the generation of exhausted-like ILC2s both in the BAL fluid and lung. Thus, the intensity or duration of stimulation changes the fate of lung ILC2s from the acquisition of immunological memory to the loss of functional exhaustion.

HETEROGENEITY OF LUNG ILC2s IN AGING

Senescence is characterized by the progressive loss of physiological function in individuals with age (65, 66). DNA damage throughout life induces “cellular senescence”, resulting in a poor proliferative capacity and irreversible cell cycle arrest, and results in a proinflammatory senescence-associated secretory phenotype (SASP) that leads individuals to low-grade, chronic inflammatory state termed as “inflamm-aging” (67–71). In mice, there is a marked increase in the expression of ILC2 progenitors in the bone marrow of aged (19–24 months old) mice compared with that in young (2–3 months old) mice; however, this increase was not observed in their progenitor cells, common helper-innate lymphoid progenitors (CHILPs) (72). Notch signaling could be involved in this increase in ILC2 progenitors with age; this pathway is specific to aged mice and is not involved in ILC2 progenitor differentiation in young mice. While the expression levels of ST2 are lower in aged ILC2 progenitors, young and aged ILC2 progenitors have the same expression level of Ki67, indicating that ILC2 progenitors of aged mice preserve the reproductive activity (72). In accordance with the increase in ILC2 progenitor expression in the bone marrow, ILC2...
progenitor populations in the peripheral blood and ILC2 populations in the peripheral blood and small intestine also increase with aging. However, since bone marrow ILC2 progenitors are rarely transferred to the lung and lung ILC2s are highly dependent on local expansion of lung-resident ILC2 progenitors, lung ILC2 populations are reduced with aging.

Functionally, aged lung ILC2s show decreased expression of Gata3, Il5, and Areg, and reduced proliferative capacity and cellular function. Indeed, aging mice are susceptible to viral infections; however, transplantation of young mouse-derived ILC2s promotes recovery from viral infections (72). Furthermore, the expression of Ehhadh and Cyp2e1, which are involved in peroxisome proliferator-activated receptors (PPAR) pathway and cytochrome P450 (CYP) activity, respectively, is downregulated in aged ILC2s, and these genes enhance IL-5 production and Areg expression independent of GATA3 involvement (72). In addition, the levels of IL-12 and IL-18, that are able to suppress Cyp2e1 expression, were increased in the lungs of aged mice, suggesting that both intrinsic and extrinsic mechanisms cause cellular senescence in lung ILC2s (72).

The effects of aging on ILC2s in humans are poorly understood. In contrast to mice, peripheral blood ILC2 populations decrease with age in humans (73). Lung ILC2 populations in humans may also be negatively correlated with aging, similar to murine lung ILC2s (35). However, studies on human lung ILC2s are not sufficiently large to allow the estimation of this trend.

DISCUSSION

Since the discovery of ILC2s about a decade ago, a large number of studies on ILC2s have been carried out, and these studies have greatly contributed to our understanding of the immunology and unraveling of the underlying pathophysiology of various human diseases. Various molecules and regulators of ILC2s have been reported, and the general features of ILC2s are widely understood. However, ILC2s have received increasing attention in the last few years because they comprise a heterogeneous cell population rather than homogeneous.

Basically, ILC2s are tissue-resident cells, and the expression levels of transcription factors and receptors of ILC2s vary among tissues. Murine lungs consist of ILC2 progenitor cells and mature ILC2s at different developmental time points in the steady state, and tissue specificity of ILC2s develops postnatally due to the lung tissue environment. Lung mature ILC2s are not only activated by IL-33 due to the high expression of IL-33 receptors, but also by other stimuli, including IL-25 and allergens. However, besides “activation,” changes in the expression of surface antigens and transcription factors vary depending on the stimulus that “activate” ILC2s, and in particular, migratory helminth infection or an intraperitoneal administration of IL-25 transiently induces intestinal-derived IILC2s in the lungs.

Recently, it has been reported that ILC2s have plasticity, and their properties are variable, such as the production of IFN-γ, IL-10, and IL-17, depending on the surrounding environment, which also contributes to the diversity of ILC2s. While the plasticity is important and a well-known concept of ILC2s, its immunological role is unclarified. Moreover, boundaries between the concept of plasticity and heterogeneity of ILCs are unclear. Furthermore, after activation, ILC2s develop training immunity; however, they sometimes cause cell exhaustion. These diversities change with the aging time scale, and cellular senescence is induced by intracellular and extracellular factors in the lungs (Figure 3).

Despite the efforts of many studies to elucidate the diversity of lung ILC2s, several questions remain unclear: Does the diversity of lung ILC2s play a distinct physiological role in vivo? If so, what would happen if lung ILC2s are homogenous and lack plasticity? Does the transcriptional heterogeneity of ILC2s, especially at steady state have a unique biological role or does it merely reflect differences in mRNA expression? Additionally, does each ILC2 subtype affect lung immunity and have clinical significance in humans?

Although human studies are also insufficient, the studies summarized in this review contribute to our understanding of disease conditions in humans. The acquisition of immunological memory may contribute to allergen-specific asthma exacerbation and non-specific allergic inflammation. Exhaustion and aging of ILC2s may limit the type 2 inflammation response, especially in geriatric patients, because these changes attenuate the effector function of ILC2s. Therefore, a greater understanding of ILC2 subsets may provide new insights into the pathophysiology of lung diseases, including asthma. In addition, targeting specific ILC2 subsets may provide a new therapeutic strategy for lung diseases.

To date, most studies have only taken a snapshot of ILC2 diversity. Therefore, diversity among ILC2s should be considered in future investigations. It is expected that future research exploring the heterogeneity of ILC2s will shed light on a variety of life science mysteries.

AUTHOR CONTRIBUTIONS

MA and HK screened articles related to this topic and wrote the manuscript. KF reviewed the manuscript critically for important intellectual content. All authors contributed to the article and approved the submitted version.

FUNDING

The work is supported by Keio University Academic Development Funds, Keio Gijuku Fukuzawa Memorial Fund for the Advancement of Education and Research, The Mochida Memorial Foundation for Medical and Pharmaceutical Research, KAKENHI, Grant-in-Aid for Young Scientists grants JP20K17193 (HK).
REFERENCES

1. Moro K, Yamada T, Tanabe M, Takeuchi T, Ikawa T, Kawamoto H, et al. Innate Production of T(H)2 Cytokines by Adipose Tissue-Associated C-Kit (+)Sca-1(+) Lymphoid Cells. *Nature* (2010) 463:540–4. doi: 10.1038/nature08636

2. Neill DR, See Wong H, Bellosi A, Flynn RJ, Daly M, Langford TKA, et al. Nuocytes Represent New Innate Eff Leukoc That Mediates Type-2 Immunity. *Nature* (2010) 464:1367–70. doi: 10.1038/nature08990

3. Price AE, Liang H-E, Sullivan BM, Reinhart RL, Eisley CJ, Erle DJ, et al. Skin-Specific Expression of IL-33 Activates Group 2 Innate Lymphoid Cells and Elicits Atopic Dermatitis-Like Inflammation in Mice. *Proc Natl Acad Sci U S A* (2010) 107:11489–94. doi: 10.1073/pnas.1003988107

4. Halier T, van der Steer CA, Matha L, Gold MJ, Martinez-Gonzalez I, McGagney KM, et al. Group 2 Innate Lymphoid Cells are Critical for the Initiation of Adaptive T Helper 2 Cell-Mediated Allergic Lung Inflammation. *Immunity* (2014) 40:425–35. doi: 10.1016/j.immuni.2014.01.011

5. Kim BS, Siracusa MC, Saenz SA, Noti M, Monticelli LA, Sonnenberg GF, et al. TSLP Elicits IL-33-Independent Innate Lymphoid Cell Responses to Promote Skin Inflammation. *Sci Transl Med* (2013) 5:170ra16. doi: 10.1126/scitranslmed.3003574

6. Imai Y, Yasuda K, Sakaguchi Y, Haneda T, Mizutani H, Yoshimoto T, et al. Skin-Specific Expression of IL-33 Activates Group 2 Innate Lymphoid Cells and Elicits Atopic Dermatitis-Like Inflammation in Mice. *Proc Natl Acad Sci U S A* (2013) 110:13921–6. doi: 10.1073/pnas.1307321110

7. Salemi M, Barlow JL, Saunders SP, Xue L, Gutowska-Owsik D, Wang X, et al. A Role for –25 and IL-33-Driven Type-2 Innate Lymphoid Cells in Atopic Dermatitis. *J Exp Med* (2013) 210:2939–50. doi: 10.1084/jem.20130351

8. Gadani SP, Smirnov I, Wilbank AT, Overall CC, Kipnis J. Characterization of Meningeal Type 2 Innate Lymphocytes and Their Response to CNS Injury. *J Exp Med* (2017) 214:285–96. doi: 10.1084/jem.20161982

9. Liang Y, Jie Z, Hou L, Aguilar-Valenzuela R, Yu D, Soong L, et al. IL-33 Induces Nuocytes and Modulates Liver Injury in Viral Hepatitis. *J Immunol* (2013) 190:5666–75. doi: 10.4049/jimmunol.1301117

10. Hayler T, Klose CSN, Souabni A, Turqusi-Neves A, Pfeifer D, Rawlins EL, et al. The Transcription Factor GATA-3 Controls Cell Fate and Maintenance of Type 2 Innate Lymphoid Cells. *Immunity* (2012) 37:634–48. doi: 10.1016/j.immuni.2012.06.020

11. Mjösberg JM, Trifari S, Crellin NK, Peters CP, van Drunen CM, Piet B, et al. Systemically Dispersed Innate IL-13-Expressing Cells in Type 2 Immunity. *J Exp Med* (2010) 210:2939–50. doi: 10.1084/jem.20130351

12. Doherty TA, Khorram N, Chang JE, Kim H-K, Rosenthal P, Croft M, et al. The Transcription Factor GATA-3 Controls Cell Fate and Maintenance of Type 2 Innate Lymphoid Cells. *Immunity* (2014) 40:425–35. doi: 10.1016/j.immuni.2014.01.011

13. Kim BS, Siracusa MC, Saenz SA, Noti M, Monticelli LA, Sonnenberg GF, et al. TSLP Elicits IL-33-Independent Innate Lymphoid Cell Responses to Promote Skin Inflammation. *Sci Transl Med* (2013) 5:170ra16. doi: 10.1126/scitranslmed.3003574

14. Imai Y, Yasuda K, Sakaguchi Y, Haneda T, Mizutani H, Yoshimoto T, et al. Skin-Specific Expression of IL-33 Activates Group 2 Innate Lymphoid Cells and Elicits Atopic Dermatitis-Like Inflammation in Mice. *Proc Natl Acad Sci U S A* (2013) 110:13921–6. doi: 10.1073/pnas.1307321110

15. Salemi M, Barlow JL, Saunders SP, Xue L, Gutowska-Owsik D, Wang X, et al. A Role for –25 and IL-33-Driven Type-2 Innate Lymphoid Cells in Atopic Dermatitis. *J Exp Med* (2013) 210:2939–50. doi: 10.1084/jem.20130351

16. Nakatsuka Y, Akiya H, Handa T, Vandenbon A, Hikichi Y, Motomura Y, et al. IL-25 Promotes ST2-Dependent Lung Fibrosis by the Induction of Alternative Activated Macrophages and Innate Lymphoid Cells in Mice. *J Allergy Clin Immunol* (2014) 134:1422–32.e11. doi: 10.1016/j.jaci.2014.05.011

17. Nakatsuka Y, Akiya H, Handa T, Vandenbon A, Hikichi Y, Motomura Y, et al. Probiotic Function of Pulmonary Group 2 Innate Lymphoid Cells is Regulated by Npnk-1. *Eur Respir J* (2021) 57:32973808. doi: 10.1183/ 13993003.00018-2020

18. Hems E, Armstrong ME, Barlow JL, Saunders SP, Schwartz C, Cooke G, et al. IL-25 and Type 2 Innate Lymphoid Cells Induce Pulmonary Fibrosis. *Proc Natl Acad Sci U S A* (2014) 111:367–72. doi: 10.1073/pnas.1315854111

19. Silver JS, Kearley J, Copenhaver AM, Sanden C, Mori M, Yu L, et al. Inflammatory Triggers Associated With Exacerbations of COPD
Asaoka et al. Heterogeneity of Lung ILC2s

36. Simony V, Fehlings M, Klaverpris HN, McGovern N, Koo S-L, Loh CY, et al. Human Innate Lymphoid Cell Subsets Possess Tissue-Type Based Heterogeneity in Phenotype and Frequency. *Immunity* (2017) 46:148–61. doi: 10.1038/immuno.2016.11.005

37. Yong Y, Tsang JCH, Wang C, Clare S, Iuewan W, Chen X, et al. Single-Cell RNA Seq Identifies a PD-1+ HI ILC Progenitor and Defines its Development Pathway. *Nature* (2016) 539:102–6. doi: 10.1038/nature20105

38. Wallrapp A, Riesenfeld SJ, Burkett PR, Abdoolnour R-EE, Nyman J, Dione D, et al. The Neuropeptide NMI Amplifies ILC2-Driven Allergic Lung Inflammation. *Nature* (2017) 549:351–6. doi: 10.1038/nature24029

39. Li S, Bostick JW, Ye J, Qui J, Zhang B, Urban JF, et al. Aryl Hydrocarbon Receptor Signaling Cell Intrinsically Inhibits Intellectual Group 2 Innate Lymphoid Cell Function. *Immunity* (2018) 49(5):915–28. doi: 10.1016/j.immuni.2018.09.015

40. Zhang J, Qu J, Zhou W, Cao J, Hu X, Mi W, et al. Neuruplin-1 Mediates Lung Tissue-Specific Control of ILC2 Function in Type 2 Immunity. *Nat Immunol* (2022) 23:237–50. doi: 10.1038/s41590-021-01097-8

41. Schneider C, Lee J, Koga S, Ricardo-Gonzalez RR, Nussbaum JC, Smith IK, et al. Tissue-Resident Group 2 Innate Lymphoid Cells Differentiated by Layered Ontogeny and in Situ Perinatal Priming. *Immunity* (2019) 50:1425–38.e5. doi: 10.1016/j.immuno.2019.04.019

42. de Kleer IM, Kool M, de Bruijn MJ, Willart M, van Moorleghem J, Schuijs MJ, et al. Perinatal Activation of the Interleukin-33 Pathway Promotes Type 2 Innate Immunity in the Developing Lung. *Immunity* (2016) 45:1285–98. doi: 10.1016/j.immuni.2016.09.034

43. Montecilli LA, Diamond JM, Saenz SA, Tait Wojno ED, Porteous MK, Cantu E, et al. Lung Innate Lymphoid Cell Composition is Altered in Primary Graft Dysfunction. *Am J Respir Crit Care Med* (2020) 19:613–22. doi: 10.1164/rccm.201906-1113OC

44. Björklund ÅK, Forkel M, Sicily P, Venn N, Theorell J, Friberg D, et al. The Heterogeneity of Human CD127+ Innate Lymphoid Cells Revealed by Single-Cell RNA Sequencing. *Nat Immunol* (2016) 17:451–60. doi: 10.1038/nj.3368

45. Castro AG, Hauser TM, Cocks BG, Abrams J, Zurawski S, Churakova T, et al. Molecular and Functional Characterization of Mouse Signaling Lymphocytic Activation Molecule (SLAM): Differential Expression and Responsiveness in Th1 and Th2 Cells. *J Immunol* (1999) 163:5860–70.

46. Alderson MR, Smith CA, Tougaw TW, Davis-Smith T, Armitage RJ, Falk B, et al. Molecular and Biological Characterization of Human 4-1BB and its Ligand. *Eur J Immunol* (1994) 24:2219–7. doi: 10.1002/eji.1830240943

47. Trompette A, Gollwitzer ES, Yadava K, Sichelstiel AK, Sprenger N, Ngom-Bru C, et al. Interleukin-33 Induces the Enzyme Tryptophan Hydroxylase 1 to Influence Its Development and Function. *J Exp Med* (2010) 208. doi: 10.1084/jem.2009.03114

48. Martinez-Gonzalez I, Mathä L, Steer CA, Ghaedi M, Poon GFT, Takei F, et al. Allergen-Experienced Group 2 Innate Lymphoid Cells Acquire Memory-Like Properties and Enhance Allergic Lung Inflammation. *Immunity* (2016) 45:198–208. doi: 10.1016/j.immuno.2016.06.017

49. Miyamoto C, Kojo S, Yamashita M, Moro K, Lacaud G, Shiroguchi K, et al. Runx/Cbfb Complexes Protect Group 2 Innate Lymphoid Cells From Exhausted-Histotype Hyporesponsiveness During Allergic Airway Inflammation. *Nat Commun* (2019) 10:447. doi: 10.1038/s41467-019-08365-0

50. Goldberger AL, Peng CK, Lipsitz LA. What is Physiologic Complexity and How Does it Change With Aging and Disease? *Neurobiol Aging* (2002) 23:2–3. doi: 10.1016/S0197-4580(01)00266-4

51. D’Azzo A, Capri F, Shiao KM, Kita R, Maric D, et al. The Limited Potential Consequences of Ageing and Senescence in Human Subjects. *Nat Immunol* (2019) 20:594107. doi: 10.3389/fimmu.2020.594107

52. Hayflick L. The Limited In Vivo Lifetime of Human Diploid Cell Strains. *Exp Cell Res* (1965) 37:614–36. doi: 10.1016/0014-4827(65)90211-9

53. Beaussier CM, Kortolica A, Galimi F, Narita M, Lowe SW, Yaswen P, et al. Reversal of Human Cellular Senescence: Roles of the P53 and P16 Pathways. *EMBO J* (2005) 24:2212–22. doi: 10.1093/emboj/cdi17

54. D’Souza SS, Shen X, Fung ITH, Ye J, Kuentzel M, Chittur SV, et al. The Limited Potential Consequences of Ageing and Senescence in Human Subjects. *Nat Immunol* (2019) 20:594107. doi: 10.3389/fimmu.2020.594107

55. Bal SM, Bernink JH, Nagasawa M, Grooth J, Shikagane MM, Golebski K, et al. IL-7, IL-4 and IL-12 Control the Fate of Group 2 Innate Lymphoid Cells in Human Airway Inflammation in the Lungs. *Nat Immunol* (2016) 17:636–45. doi: 10.1038/nj.3344

56. Ohne Y, Silver JS, Thompson-Snipes L, Collet MA, Blanck JP, Cantarel BL, et al. IL-17 is a Critical Regulator of Group 2 Innate Lymphoid Cell Function and Plasticity. *Nat Immunol* (2016) 17:646–55. doi: 10.1038/nj.3347

57. Goldberger AL, Peng CK, Lipsitz LA. What is Physiologic Complexity and How Does it Change With Aging and Disease? *Neurobiol Aging* (2002) 23:2–3. doi: 10.1016/S0197-4580(01)00266-4

58. Li NW, Kairui M, Chen X, Sun M-A, Kawabe T, Li W, et al. S1P-Dependent Alternative Activation Generates IL-10 Producing Type 2 Innate Lymphoid Cells. *Nat Commun* (2017) 8:1900. doi: 10.1038/s41467-017-02023-z

59. Martinez-Gonzalez I, Mathä L, Steer CA, Ghaedi M, Poon GFT, Takei F, et al. Allergen-Experienced Group 2 Innate Lymphoid Cells Acquire Memory-Like Properties and Enhance Allergic Lung Inflammation. *Immunity* (2016) 45:198–208. doi: 10.1016/j.immuno.2016.06.017

60. Hayflick L. The Limited In Vivo Lifetime of Human Diploid Cell Strains. *Exp Cell Res* (1965) 37:614–36. doi: 10.1016/0014-4827(65)90211-9

61. Beaussier CM, Kortolica A, Galimi F, Narita M, Lowe SW, Yaswen P, et al. Reversal of Human Cellular Senescence: Roles of the P53 and P16 Pathways. *EMBO J* (2005) 24:2212–22. doi: 10.1093/emboj/cdi17

62. D’Souza SS, Shen X, Fung ITH, Ye J, Kuentzel M, Chittur SV, et al. The Limited Potential Consequences of Ageing and Senescence in Human Subjects. *Nat Immunol* (2019) 20:594107. doi: 10.3389/fimmu.2020.594107

Conflict of Interest: The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Publisher’s Note: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or other products marketed by the company owning the journal, has not been influenced by the authors or anyone associated with the publication of this article.
this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.

Copyright © 2022 Asaoka, Kabata and Fukunaga. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.